🚀 VC round data is live in beta, check it out!
Dicot Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dicot Pharma and similar public comparables like Pliant Therapeutics, BioStem Technologies, aTyr Pharma, NRX Pharmaceuticals and more.
Dicot Pharma Overview
About Dicot Pharma
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation better than existing preparations. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects and also used in the treatment of erectile dysfunction and premature ejaculation.
Founded
N/A
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$75M
Dicot Pharma Financials
Dicot Pharma reported last fiscal year revenue of — and negative EBITDA of ($9M).
In the same fiscal year, Dicot Pharma generated ($9M) in EBITDA losses and had net loss of ($9M).
Dicot Pharma P&L
In the most recent fiscal year, Dicot Pharma reported revenue of — and EBITDA of ($9M).
Dicot Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($9M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($9M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dicot Pharma Stock Performance
Dicot Pharma has current market cap of $83M, and enterprise value of $75M.
Market Cap Evolution
Dicot Pharma's stock price is $0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $75M | $83M | 0.4% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDicot Pharma Valuation Multiples
Dicot Pharma trades at (8.6x) EV/EBITDA.
Dicot Pharma Financial Valuation Multiples
As of April 18, 2026, Dicot Pharma has market cap of $83M and EV of $75M.
Equity research analysts estimate Dicot Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dicot Pharma has a P/E ratio of (9.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $83M | XXX | $83M | XXX | XXX | XXX |
| EV (current) | $75M | XXX | $75M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.4x) | XXX | XXX | XXX |
| P/E | — | XXX | (9.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dicot Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dicot Pharma Margins & Growth Rates
Dicot Pharma's revenue in the last fiscal year grew by —.
Dicot Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $4.5M for the same period.
Dicot Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dicot Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dicot Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pliant Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BioStem Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| aTyr Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| NRX Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Seres Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dicot Pharma M&A Activity
Dicot Pharma acquired XXX companies to date.
Last acquisition by Dicot Pharma was on XXXXXXXX, XXXXX. Dicot Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dicot Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDicot Pharma Investment Activity
Dicot Pharma invested in XXX companies to date.
Dicot Pharma made its latest investment on XXXXXXXX, XXXXX. Dicot Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dicot Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dicot Pharma
| Where is Dicot Pharma headquartered? | Dicot Pharma is headquartered in Sweden. |
| How many employees does Dicot Pharma have? | As of today, Dicot Pharma has over 2 employees. |
| Is Dicot Pharma publicly listed? | Yes, Dicot Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Dicot Pharma? | Dicot Pharma trades under DICOT ticker. |
| When did Dicot Pharma go public? | Dicot Pharma went public in 2018. |
| Who are competitors of Dicot Pharma? | Dicot Pharma main competitors are Pliant Therapeutics, BioStem Technologies, aTyr Pharma, NRX Pharmaceuticals. |
| What is the current market cap of Dicot Pharma? | Dicot Pharma's current market cap is $83M. |
| Is Dicot Pharma profitable? | No, Dicot Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.